Sanofi Exit From Sickle Cell Gene Therapy Leaves Sangamo With Difficult Decision

Adds To Hemophilia A Problems

 
• By Andrew McConaghie

Sanofi’s decision is influenced by its own in-house options, but also by the growing competition in sickle cell gene therapy.

Sangamo
Sanofi's decision means Sangamo has just pharma partner left - Pfizer - among its clinical trial programs. • Source: Alamy

Sanofi is to hand back the rights to Sangamo Therapeutics’s gene-edited cell therapy for sickle cell disease (SCD), SAR445136, after deciding to focus instead on allogeneic cell therapies.

The Paris-headquartered pharma company announced on 6 January that it would return the rights to the candidate during the first half of 2022 – despite promising preliminary Phase I/II data

More from Business

More from Scrip